Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice
Open Access
- 1 May 2023
- journal article
- research article
- Published by Elsevier BV in Heliyon
- Vol. 9 (5), e15587
- https://doi.org/10.1016/j.heliyon.2023.e15587
Abstract
No abstract availableFunding Information
- Academia Sinica
This publication has 49 references indexed in Scilit:
- Development of therapeutic antibodies for the treatment of diseasesJournal of Biomedical Science, 2020
- Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancerCancer Science, 2019
- mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In VivoMolecular Therapy, 2019
- How mRNA therapeutics are entering the monoclonal antibody fieldJournal of Translational Medicine, 2019
- mRNA as novel technology for passive immunotherapyCellular and Molecular Life Sciences, 2018
- SWISS-MODEL: homology modelling of protein structures and complexesNucleic Acids Research, 2018
- mRNA mediates passive vaccination against infectious agents, toxins, and tumorsEMBO Molecular Medicine, 2017
- Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large AnimalsMolecular Therapy, 2015
- Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding ErythropoietinMolecular Therapy, 2012
- Optimization of primer sequences for mouse scFv repertoire display library constructionNucleic Acids Research, 1994